Bruker shares tumble 7% as Q2 on earnings miss, guidance cut

Published 04/08/2025, 12:22
 Bruker shares tumble 7% as Q2 on earnings miss, guidance cut

BILLERICA, Mass. - On Monday, Bruker Corporation (NASDAQ:BRKR) reported second-quarter earnings that missed analyst expectations and significantly reduced its full-year outlook, citing challenging demand conditions across multiple markets.

The scientific instrument maker’s shares fell 7.84% in pre-market trading after the earnings release.

The company reported second-quarter adjusted earnings of $0.32 per share, falling well short of the $0.42 analyst consensus. Revenue came in at $797.4 million, below the expected $812.81 million and down 0.4% YoY. Organic revenue declined 7.0% compared to the same period last year.

"Life-science research instruments demand is under pressure at the moment," said Frank H. Laukien, Bruker’s President and CEO. "Our second quarter came in below expectations, as we experienced challenging demand conditions in the US academic market, as well as in biopharma and industrial markets."

In response to the difficult operating environment, Bruker announced an expanded cost savings initiative expected to reduce annual costs by $100-$120 million in fiscal 2026. The company also slashed its full-year 2025 guidance, now projecting revenue of $3.43-$3.50 billion (previously $3.52 billion consensus) and adjusted EPS of $1.95-$2.05, well below the $2.42 analyst estimate and down from $2.41 in fiscal 2024.

The company’s operating margin deteriorated significantly, with non-GAAP operating margin falling to 9.0% in Q2 2025 from 13.8% in the year-ago period.

Laukien expressed optimism for a partial demand recovery in fiscal 2026, noting the company’s "successful track record of rebounding very strongly from previous market disruptions." However, the immediate outlook remains challenging as Bruker works to gain "improved visibility into US academic funding trends, China stimulus, finalized tariffs, as well as into the timing of a recovery in biopharma drug discovery and industrial research instruments demand."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.